Introduction
Chronic myeloid leukemia (CML) is a clonal neoplastic disorder of hematopoietic stem cells that accounts for 15-20% of newly diagnosed cases of adult leukemia. The causative molecular event in CML is the genomic reciprocal translocation t(9;22)(q34;q11), which results in the formation of the Philadelphia (Ph) chromosome. As a consequence of this genomic rearrangement, the bcr gene on chromosome 22 is fused to the abl gene on chromosome 9, resulting in a novel chimeric bcr-abl gene. This fusion gene is expressed as a BCR-ABL fusion protein with deregulated tyrosine kinase activity and has been shown to play a key role in the pathogenesis of CML. 1 The clinical course of CML is characteristically triphasic, initially comprising a chronic phase (CP) of variable duration that may last up to several years, followed by a more or less rapid progression through an accelerated phase (AP) to blast crisis (BC). [1] [2] [3] The mechanisms responsible for transition of CML-CP into BC remain poorly understood, although it is generally accepted that an unrestrained BCR-ABL activity in hematopoietic stem/progenitor cells is the primary determinant of disease progression. Therefore, the degree of tumor load reduction, that is, the residual amount of Ph þ cells, serves as an important prognostic factor in CML therapy. [4] [5] [6] The current model of CML progression is based on the assumption that an increased and/or continuous BCR-ABL expression promotes consecutive molecular and chromosomal changes. This leads to an accumulation of additional genetic aberrations and changes in gene expression which result in the expansion of differentiation-arrested and increasingly malignant cell clones. 2, 7 In addition, molecular changes such as mutations in p53, p16/ARF, Rb, and ras, and characteristic cytogenetic alterations become detectable in the vast majority of CML patients during evolution to BC. In fact, up to 80% of patients with CML develop additional nonrandom chromosomal abnormalities involving chromosomes 8, 17, 19, and 22. Of these, duplication of the Ph chromosome or gain of whole chromosomes (trisomy 8, trisomy 19) are the most frequent alterations. 8 Such massive genomic changes, collectively known as aneuploidy, are characteristic features of most human tumors and are thought to further destabilize cancer cells genomically in an autocatalytic manner. [9] [10] [11] Recent experimental work strongly suggests that aneuploidy share responsibility with intragenic mutations during the multi-step model of tumorigenesis. [12] [13] [14] Several studies have provided evidence that centrosome aberrations are closely associated with chromosome missegregation and constitute the possible cause of aneuploidy observed in solid tumors and hematologic malignancies. [15] [16] [17] [18] [19] [20] [21] Centrosomes are cellular organelles consisting of a pair of barrel-shaped microtubule assemblies called centrioles that are embedded in an amorphous pericentriolar matrix of about 250 interacting proteins. 22, 23 They play a vital role in eukaryotic cells and serve as microtubule-organizing centers (MTOC), controlling number, cell polarity, and orientation of cytoplasmic microtubules. Centrosomes are essential for organization of the mitotic spindle, which mediates the strictly bipolar separation of chromosomes during mitosis. Centrosome duplication is precisely controlled and tightly linked to the cell division cycle via cyclin-dependent kinase (cdk) 2 activity. 24 Recent advances in molecular and functional analysis of centrosome-associated proteins suggest that centrosomes are not only structural organelles but also serve as regulatory integrators of positive and negative pathways for mitotic entry. 25 Therefore, any defect impairing the fidelity of centrosome function may influence cell proliferation and chromosomal stability. 26 Consequently, the impact of centrosome defects on generation of invasive, genetically unbalanced cells during cancer progression is under discussion. 12, 27 Since CML as a monocausal disease with relatively slow progress towards malignant transformation constitutes an excellent model system for biological studies of neoplastic disorders, we considered it well suited for the investigation of the relationship between centrosome aberrations and chromosomal instability. In this study, we comparatively analyzed the centrosome and karyotype status of CD34 30 In the group of CP patients, 11/18 (61%) showed bcr-abl rearrangements of the b3a2 type, four expressed b2a2 (22%) fusion transcripts, and three (17%) had both fusion products as determined by multiplex RT-PCR. 31 In BC patients, 8/16 patients (50%) expressed b3a2, 4/16 (25%) patients b2a2, and three patients both fusion transcripts (19%), while one patient displayed an e19a2 bcr-abl transcript (6%). One patient showed loss of the Y chromosome in 5/15 metaphases (45,X,-Y,t(9;22)(q34;q11)) at the time of diagnosis. Umbilical cord blood specimens (n ¼ 11) including five males and six females were obtained from the local blood transfusion center (Institut fü r Transfusionsmedizin und Immunologie, DRK-Blutspendedienst, Mannheim, Germany) and served as control samples (NC).
Preparation of CD34 þ Ph þ cells
For enrichment of mononuclear cells, Ficoll-Paque Plus separation was performed according to the manufacturer's protocol (Amersham Bioscience, Uppsala, Sweden). Subsequently, CD34 þ cells were isolated to 95-98% purity by using the Direct CD34 þ Progenitor Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
Centrosome staining and digital immunofluorescence
For centrosome immunostaining, cytospins of CD34 þ cells were prepared. 5 Â 10 4 cells were mounted on coated slides (Langenbrinck GmbH, Teningen, Germany) and fixed in À201C methanol for 30 min, blocked in 1 Â PBS and 2% horse serum for 1 h at 371C, then followed by indirect immunostaining. Cytospins were incubated for 30 min at 41C with a polyclonal antibody to pericentrin (Covance, Richmond, CA, USA) at a dilution of 1:1000 in 1 Â PBS containing 2% horse serum. Subsequently, 1:1000 solution of Cy3-conjugated goat antirabbit IgG antibody (Jackson Immunoresearch Laboratories Inc., West Grove, PA, USA) was used for detection of antibodyantigen complexes. Slides were mounted in Vectashield Mounting Medium containing DAPI for nucleus staining (Vector Laboratories, Burlingame, CA, USA). An arbitrarily chosen set of the same slides was co-stained with mouse monoclonal antibody to gamma-tubulin (Sigma, Deisenhofen, Germany) and FITC anti-mouse IgG (Fab-specific) from goat as secondary antibody (Sigma, Deisenhofen, Germany). Co-localization of both centrosome-associated proteins, pericentrin and gamma-tubulin, confirmed the specificity of obtained immunofluorescence signals. Immunostained cells were visualized by fluorescence microscopy (Axioskop, Zeiss AG, Jena, Germany) using a Zeiss Plan Neofluar Â 100/1.30 Oil objective and Quips SmartCapture Software Package (Applied Imaging International Ltd, Newcastle, UK) under automatic exposure settings.
Cytogenetics
Chromosome analyses were performed on CD34 þ cells from peripheral blood or on bone marrow samples of CML patients and on CD34 þ cells of umbilical cord blood samples from healthy newborns. In brief, cells were cultured in RPMI 1640 medium (Invitrogen, Groningen, Netherlands) with 10% fetal calf serum, antibiotics, and antimycotics. Cord blood cultures were stimulated with an additional cytokine cocktail containing IL3, IL6, GM-CSF, SCF, and flt3 ligand. 32 Bone marrow cultures were cultivated for 24 h, cord blood cultures for 48 or 72 h before standard treatment with Colcemid. Metaphases were analyzed for G-bands using a modified GAG-banding technique as described. 33 Analysis and interpretation of chromosomes were performed according to the International System for Human Cytogenetic Nomenclature. 34 
Evaluation and calculation of centrosome aberrations
Immunostaining of centrosomes was judged satisfactory when the characteristic single or paired centrosome pattern was detectable in nonmalignant CD34 þ cells of umbilical cord blood samples concomitantly analyzed in most experiments. Centrosomes were considered structurally abnormal if their diameter was at least twice that of centrosomes in normal control cells or if they displayed structural abnormalities as described by others. 16, 21 Numeric aberrations were stated, if centrosomes were present in numbers 42. At least 100 cells per sample were examined. Centrosome aberration percentages reflect the number of cells with numerical and/or structural centrosome abnormalities per 100 cells counted. Each immunostained cell was counted only once irrespective of the fact that both types of centrosome aberrations may be present in a single cell. Image processing (i.e. cropping, sizing, and contrast adjustment) was performed using Adobe Photoshop v5.5 on an IBM compatible personal computer.
Statistical analysis
For statistical evaluation, pairwise comparisons of differences in the distribution of the percentage of cells with abnormal centrosomes between the diagnostic groups NC, CP, and BC were carried out using the Mann-Whitney test. For three-group comparisons, the Kruskal-Wallis test was employed. For arbitrary random sample analysis, the Wilcoxon-signed rank test was used. An effect was considered as statistically significant at P-values p0.05. Statistical analyses were [25] CP, chronic phase (at time of initial diagnosis); m-BC, myeloid blast crisis; l-BC, lymphoid blast crisis; m, male; f, female; F, not applicable.
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Results and discussion
To investigate whether centrosome aberrations occur in CML blasts and, if present, correlate with chromosomal alterations associated with blast transformation and progression to BC, we examined a set of CML samples by using indirect immunofluorescence with antibodies to the centrosomal proteins pericentrin and gamma-tubulin. To obtain sufficient CD34 þ Ph þ blasts/progenitor cells from peripheral blood for centrosome analysis, only patients before therapy (at time of diagnosis) and patients in AP or BC were selected for this study. CD34 þ cells (100% Ph þ ) isolated from 34 fresh peripheral blood samples of CML patients were analyzed, including 18 specimens at the time of diagnosis (in CP) and 16 BC samples (Table 1) . CD34 þ cells isolated from 11 umbilical cord blood specimens served as negative controls. All 34 CML patients under investigation displayed numerical and structural centrosome aberrations when compared to the control samples ( Figure 1 ). In CP samples no correlation between prognostic score (Hasford) and the percentage of centrosome aberrant cells could be stated. On average, centrosome abnormalities were found in 29.175.9% of CP blasts and in 54.374.8% blasts of BC samples, but in only 2.471.1% of the controls (Pp0.0001). Nearly identical results were obtained comparing pericentrin and gamma-tubulin stainings in a randomly chosen subgroup of the samples (data not shown). These findings indicate that centrosome defects are a common feature in CML. They represent one of the very first neoplastic steps as they can be observed in all patients at the time of diagnosis (CP). In BC samples, nearly double the amount of CD34 þ blasts with centrosome alterations was found (Figure 1) , suggesting an association of centrosome alterations with the malignant phenotype. Besides this quantitative effect, blastic transformation of CD34 þ progenitor cells also seems to influence the phenotype of centrosome abnormalities. As shown in Figure 2 , where representative subsets of pericentrin-immunostained centrosomes from normal cells (panel a), CP blasts (panel b), and BC blasts (panel c) are comparatively shown, blasts from CP (b 1-9) display mostly numerical aberrations with a uniform centrosome morphology close to that found in normal CD34 þ cells (a 1-3) . Very rarely, amorphous amplifications of pericentrin-associated centrosomal material can be detected (b 2) at this disease stage. This is in strong contrast to the centrosome morphologies observed in cells from BC where an irregularly shaped amorphous amplification of pericentrinassociated centrosomal material prevails (c 2, 6, 7, 9). Such cells display both numerical and morphological centrosome alterations at a high rate.
Pericentrin is a 220-kDa coiled-coil protein of the pericentriolar matrix anchoring gamma-tubulin complexes responsible for microtubule nucleation at centrosomes. The protein is required for proper spindle organization and the loss of this anchoring system elicits a checkpoint response that prevents Figure 1 Correlation between centrosome and chromosomal aberrations in CD34 þ cells isolated from umbilical cord blood (NC) specimen (n ¼ 11) and in CD34 þ Ph þ cells from 34 CML patients in CP (n ¼ 18) and BC (n ¼ 16).
Figure 2
Centrosome aberrations in CML. Indirect immunofluorescence staining of centrosomes in normal CD34 þ cells isolated from umbilical cord blood (NC, panel a) and in CD34 þ Ph þ blasts from CML patients in CP (panel b) and BC (panel c). Cells were immunostained with an antibody to pericentrin, followed by a Cy3-conjugated secondary antibody.
Centrosome aberrations in CML M Giehl et al mitotic entry and triggers apoptotic cell death in normal cells. 22, 35 In CML blasts, however, the amount of pericentrin is clearly amplified, as demonstrated by our analysis indicating severe alterations in cell polarity and chromosome segregation. The presence of excess pericentriolar material has been associated with a high frequency of abnormal mitoses and centrosome abnormalities are hypothesized to confer a mutator phenotype to tumors, yielding cells with a selective advantage and a more aggressive state. 36 Thus, acquisition of centrosome defects in CML-CP progenitor cells prior to diagnosis and its significant increase during the course of the disease may be considered as one of the driving forces of progression in CML.
To test the relationship between the occurrence of centrosome alterations and additional karyotypic abnormalities, we compared the centrosome aberration patterns of the 34 CML patients with the corresponding cytogenetic data sets (Table 1) . For newly diagnosed patients, karyotype analysis was routinely performed on bone marrow samples. For BC patients, CD34 þ Ph þ blasts from bone marrow and from peripheral blood were analyzed, yielding identical cytogenetic data irrespective of the type of sample. Cells for cytogenetic analysis and for centrosome immunostaining were taken at the same or similar time points.
Normal karyotypes were found in CD34 þ control cells ( Figure 1 ). All CML CP samples were Ph positive. Additionally, one CP patient displayed a loss of the Y chromosome in 67% of analyzed tumor cells at the time of diagnosis. In contrast, 11/16 (73%) CML patients in BC showed additional chromosomal aberrations of varying complexity, while five patients only had the Ph translocation. Additional chromosomal aberrations in the BC sample group were found in 48.7% of analyzed cells (median 54%). This is in contrast to CP samples were additional chromosome aberrations were only detected in one patient (reflecting 3.7% of the total number of analyzed cells in the CP patient group, median 0%, P ¼ 0.0005). Our data are in agreement with several other studies, providing evidence that centrosome aberrations result in chromosomal missegregation and accelerate malignant transformation. 12, 18, 24, 37 For some cancers, it has been demonstrated that aneuploid DNA content can be a reliable indicator for malignant transformation and tumor progression. 38 We were able to show that centrosome aberrations in CML are detectable before secondary chromosomal aberrations, leading to a change in ploidy, become evident. Increase in the percentage of centrosome aberrant cells is significantly correlated with karyotype instability and aneuploidy (P ¼ 0.0005), but seems independent from karyotypic phenotype. Therefore, we conclude that centrosome aberrations contribute to the acquisition of chromomal instability seen in CML-BC. The resulting aneuploidy may, by means of altered gene-dosage effects, further promote genetic destabilization of tumor cells and lead to selection of more agressive blast clones. Since p53 mutations and an altered retinoblastoma (Rb) phosphorylation status -both proteins known to be regulated by BCR-ABL -are involved in centrosome hyperamplification and centrosome duplication, 18, 37, 39 we hypothesize that BCR-ABL activity in hematopoietic progenitor cells may be responsible for the loss of centrosome stability. In addition to other unknown mechanisms, the effect may be brought about by mutations or an altered activity in the p53 tumor suppressor protein that has been demonstrated to be associated with centrosomes during mitosis and to be essential for centrosome duplication control. 40 Thus, centrosome alterations induced by BCR-ABL might function as an additional 'amplifier' of a genetically unstable phenotype and contribute to the expansion of cell clones with increasingly malignant characteristics. 2 In conclusion, our results indicate that centrosome defects are an early detectable feature in CML. Centrosome aberrations may be BCR-ABL-triggered and may contribute to the acquisition of karyotype instability and aneuploidy in CML progenitor cells. Since the extent of centrosome abnormalities strongly correlates with the stage of disease, we conclude that the centrosome status in CD34 þ Ph þ cells of patients has prognostic value that merits further studies in the future.
